A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

The federal agency’s new alert is about counterfeit drugs claiming to have semaglutide — the key ingredient in weight loss ...

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Wegovy contains the same main ingredient as Ozempic, semaglutide, and is FDA-approved for weight loss in people with obesity or who are overweight with at least one weight-related condition. It is ...

Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Very few people are currently being prescribed drugs for weight loss on the NHS in Scotland, research by BBC Scotland News ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...